GSK quietly reveals just how much cash they used to buy a chunk of the Bay Area's buzziest startup
As we reported last fall, GlaxoSmithKline R&D chief Hal Barron was gung ho over the prospects of teaming up with Rick Klausner and his startup Lyell Immunopharma. Their alliance was billed as a path to cell therapy 2.0 — including key players in overcoming the limitations to Generation 1. But the pharma giant wasn’t keen to publicly disclose just how much money was going into Lyell.
Until now, when the accountants and lawyers are in charge of public disclosures.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.